Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally.
Adequate balance sheet and fair value.
Share Price & News
How has Jazz Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: JAZZ has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: JAZZ underperformed the US Pharmaceuticals industry which returned 5.6% over the past year.
Return vs Market: JAZZ underperformed the US Market which returned 5.3% over the past year.
Price Volatility Vs. Market
How volatile is Jazz Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
6 days ago | Simply Wall StJazz Pharmaceuticals plc (NASDAQ:JAZZ) Looks Just Right
4 weeks ago | Simply Wall StJazz Pharmaceuticals plc (NASDAQ:JAZZ) On An Uptrend: Could Fundamentals Be Driving The Stock?
1 month ago | Simply Wall StInsider Buying: The Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Independent Director Just Bought 4.5% More Shares
Is Jazz Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: JAZZ ($107.31) is trading below our estimate of fair value ($249.9)
Significantly Below Fair Value: JAZZ is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: JAZZ is poor value based on its PE Ratio (21.6x) compared to the US Pharmaceuticals industry average (20.4x).
PE vs Market: JAZZ is poor value based on its PE Ratio (21.6x) compared to the US market (16.1x).
Price to Earnings Growth Ratio
PEG Ratio: JAZZ is poor value based on its PEG Ratio (1.1x)
Price to Book Ratio
PB vs Industry: JAZZ is good value based on its PB Ratio (2.1x) compared to the US Pharmaceuticals industry average (3.2x).
How is Jazz Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: JAZZ's forecast earnings growth (19.4% per year) is above the savings rate (2.2%).
Earnings vs Market: JAZZ's earnings (19.4% per year) are forecast to grow slower than the US market (22.5% per year).
High Growth Earnings: JAZZ's earnings are forecast to grow, but not significantly.
Revenue vs Market: JAZZ's revenue (2.1% per year) is forecast to grow slower than the US market (9.2% per year).
High Growth Revenue: JAZZ's revenue (2.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: JAZZ's Return on Equity is forecast to be high in 3 years time (21.1%)
How has Jazz Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: JAZZ has a large one-off loss of $447.3M impacting its March 31 2020 financial results.
Growing Profit Margin: JAZZ's current net profit margins (12.8%) are lower than last year (25%).
Past Earnings Growth Analysis
Earnings Trend: JAZZ's earnings have grown by 12.2% per year over the past 5 years.
Accelerating Growth: JAZZ's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: JAZZ had negative earnings growth (-42.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (16.1%).
Return on Equity
High ROE: JAZZ's Return on Equity (10%) is considered low.
How is Jazz Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: JAZZ's short term assets ($1.5B) exceed its short term liabilities ($396.1M).
Long Term Liabilities: JAZZ's short term assets ($1.5B) do not cover its long term liabilities ($2.0B).
Debt to Equity History and Analysis
Debt Level: JAZZ's debt to equity ratio (57.6%) is considered high.
Reducing Debt: JAZZ's debt to equity ratio has reduced from 102.8% to 57.6% over the past 5 years.
Debt Coverage: JAZZ's debt is well covered by operating cash flow (52.4%).
Interest Coverage: JAZZ's interest payments on its debt are well covered by EBIT (9x coverage).
What is Jazz Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate JAZZ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate JAZZ's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if JAZZ's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if JAZZ's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of JAZZ's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Bruce Cozadd (56yo)
Mr. Bruce C. Cozadd co-founded Jazz Pharmaceuticals Public Limited Company in 2003 and has been Chairman and Chief Executive Officer since April 2009 and served as its Interim Principal Financial Officer f ...
CEO Compensation Analysis
Compensation vs Market: Bruce's total compensation ($USD14.71M) is above average for companies of similar size in the US market ($USD7.39M).
Compensation vs Earnings: Bruce's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
|President & COO||2.5yrs||US$4.71m||0.014% $846.9k|
|Senior VP & General Counsel||1yr||US$3.21m||no data|
|Executive Vice President of Research & Development||1.17yrs||US$3.69m||0.0041% $241.7k|
|Executive VP & CFO||0.33yr||no data||no data|
|Vice President of Finance & Principal Accounting Officer||0.92yr||no data||0.012% $697.3k|
|Senior Vice President of Technical Operations||0.75yr||no data||0.0070% $414.0k|
|Vice President of Investor Relations||no data||no data||no data|
|Senior VP & Chief Human Resources Officer||1.67yrs||no data||no data|
|Executive Vice President of Special Projects||6.25yrs||US$2.86m||0.017% $1.0m|
|Senior Vice President of Sleep & CNS Medicine||no data||no data||no data|
Experienced Management: JAZZ's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
|Independent Director||16.5yrs||US$535.07k||0.015% $876.6k|
|Independent Director||8.5yrs||US$542.57k||2.08% $123.5m|
|Independent Director||7.17yrs||US$557.57k||0.013% $793.5k|
|Independent Director||7.17yrs||US$555.07k||0.010% $618.9k|
|Independent Director||11yrs||US$547.57k||0.028% $1.7m|
|Independent Director||10.5yrs||US$532.57k||0.011% $648.6k|
|Lead Independent Director||6.17yrs||US$580.07k||0.0045% $268.5k|
|Independent Director||5.92yrs||US$542.57k||0.0095% $566.0k|
|Independent Director||8yrs||US$542.57k||0.013% $743.6k|
|Independent Director||7.17yrs||US$567.57k||0.012% $721.0k|
|Independent Director||1.42yrs||US$1.23m||0.0017% $101.6k|
Experienced Board: JAZZ's board of directors are considered experienced (7.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: JAZZ insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Jazz Pharmaceuticals plc's company bio, employee growth, exchange listings and data sources
- Name: Jazz Pharmaceuticals plc
- Ticker: JAZZ
- Exchange: NasdaqGS
- Founded: 2003
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$5.939b
- Shares outstanding: 55.35m
- Website: https://www.jazzpharma.com
Number of Employees
- Jazz Pharmaceuticals plc
- Waterloo Exchange
- Fifth Floor
- Co. Dublin
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|JAZZ||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Jun 2007|
|J7Z||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jun 2007|
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adult and pediatric patients with narcolepsy; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; and Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia. The company also offers JZP-258, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for some narcolepsy patients; JZP-385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP-458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and lurbinectedin, a product candidate under clinical investigation for the treatment of patients with relapsed small cell lung cancer. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma. The company was founded in 2003 and is headquartered in Dublin, Ireland.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/14 23:56|
|End of Day Share Price||2020/07/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.